Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05024175 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Follow-up of Subjects Treated With CAR T Cells

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 7 words Study description revised Show 1 more changeShow less
    • Study description revised
  2. 2 versions Re-verified since Sep 26, 2025, no change to tracked fieldsv4-v5
  3. Lead sponsor: Massachusetts General Hospital to Marcela V. Maus, M.D.,Ph.D. Site contact updatedv3 Show 1 more changeShow less
    • Site contact updated
  4. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 18 to 45 · Start date changed from estimate of Dec 2021 to Aug 7, 2023 · Primary endpoints revised (15) · 4 morev2 Show 7 more changesShow less
    • Enrollment target: 18 to 45
    • Start date changed from estimate of Dec 2021 to Aug 7, 2023
    • Primary endpoints revised (15)
    • Eligibility criteria shortened, about 39 words
    • Study description shortened, about 36 words
    • Site details revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.
Trial Details
NCT Number NCT05024175
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Conditions Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov